



Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

January 23, 2020

www.biocon.com

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol- Biocon

Subject: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the un-audited financial results (consolidated and standalone) as per Indian Accounting Standard (Ind-AS) along with Limited Review Report for the quarter and nine months ended December 31, 2019. A copy of the un-audited financial results along with the Limited Review Report is enclosed herewith.

The above information will also be available on the website of the Company at www.biocon.com.

Further, the Board Meeting commenced at 3:30 pm and concluded at 6:15 pm.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma



Mayank Verma
Company Secretary and Compliance Officer

Enclosed:

- Un-audited financial results (consolidated and standalone);
- Limited Review Report.

B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park
Pebble Beach, B Block, 3rd Floor
Off Intermediate Ring Road
Bengaluru 560 071 India

Telephone +91 80 4682 3000
Fax +91 80 4682 3999

Limited review report

To
The Board of Directors of Biocon Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Biocon Limited (“the Company”) for the quarter ended December 31, 2019 and year to date results for the period from April 01, 2019 to December 31, 2019 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co. LLP**

Chartered Accountants

Firm's Registration Number: 101248W/W-100022



S Sethuraman

Partner

Membership Number. 203491

UDIN: 20203491AAAAAD4598

Place: Bengaluru

Date: January 23, 2020

Limited review report

To

The Board of Directors of Biocon Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Biocon Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), and its share of the net loss after tax and total comprehensive loss of its associate and a joint venture for the quarter ended December 31, 2019 and year to date results for the period from April 01, 2019 to December 31, 2019 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
 1. Biocon Limited
 2. Syngene International Limited
 3. Biocon Research Limited
 4. Biocon Pharma Limited
 5. Biocon Biologics India Limited
 6. Biocon Biologics Limited
 7. Biocon Academy
 8. Biocon SDN. BHD
 9. Biocon SA
 10. Biocon FZ LLC
 11. Biocon Pharma Inc.
 12. Biocon Healthcare SDH. BHD
 13. Syngene USA Inc.
 14. Biocon Pharma UK Limited
 15. Biocon Pharma Ireland Limited
 16. Bicara Therapeutics Inc.
 17. Biocon India Limited Employee Welfare Trust

Limited review report (continued)

18. Biocon Limited Employee Welfare Trust
 19. Syngene International Limited Employee Welfare Trust
 20. Biocon Biosphere Limited
 21. Biocon Biologics Inc.
 22. NeoBiocon FZ LLC
 23. Iatrica Inc.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of a subsidiary included in the Statement, whose interim financial information reflect total revenues (including other income) of Rs. 580 million and Rs. 1,914 million, total net loss after tax of Rs. 1,047 million and Rs. 2,104 million and total comprehensive loss of Rs. 1,029 million and Rs. 2,125 million, for the quarter ended December 31, 2019 and for the period from April 01, 2019 to December 31, 2019, respectively, as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also includes the Group's share of net loss after tax of Rs. 32 million and Rs. 205 million and total comprehensive loss of Rs. 32 million and Rs. 205 million for the quarter ended December 31, 2019 and for the period from April 01, 2019 to December 31, 2019, respectively, as considered in the Statement, in respect of a joint venture, whose interim financial information have not been reviewed by us. The interim financial information of the subsidiary and joint venture both incorporated outside India have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by the other auditors under auditing standards applicable in their respective countries whose reports have been furnished to us by the Management. The Parent's Management has converted the interim financial information of the subsidiary and joint venture both incorporated outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed this conversion adjustments, if any made by the Parent's Management. Our opinion in so far as it relates to the balances and affairs of such subsidiary and joint venture both incorporated outside India is based solely on the reports of the other auditors and the procedure performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matter.

for B S R & Co. LLP
Chartered Accountants
Firm's Registration Number: 101248W/W-100022


S Sethuraman
Partner
Membership Number. 203491
UDIN: 20203491AAAAAC6577

Place: Bengaluru
Date: January 23, 2020

BIOCON LIMITED

CIN: L24234KA1978PLC003417 Website: www.biocon.com

Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE - 560 100

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(Rs. in Million, except per equity share data)

Sl. No.	Particulars	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Previous Year ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Continuing operations						
1	Income						
	Revenue from operations	5,013	5,239	4,434	15,060	13,229	17,857
	Other income	512	603	351	1,345	958	1,089
	Total income	5,525	5,842	4,785	16,405	14,187	18,946
2	Expenses						
	a) Cost of raw materials and packing materials consumed	1,735	2,261	2,180	6,109	5,673	8,066
	b) Purchases of traded goods	207	286	192	701	446	510
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	123	(392)	(473)	(669)	(209)	(691)
	d) Employee benefits expense	878	849	731	2,549	2,097	2,891
	e) Finance costs	1	4	8	10	20	26
	f) Depreciation and amortisation expenses	253	241	234	734	689	923
	g) Other expenses	1,329	1,336	1,408	3,973	3,562	4,982
		4,526	4,585	4,280	13,407	12,278	16,707
	Less: Recovery of cost from co-development partners (net)	(29)	-	(4)	(29)	(20)	(4)
	Total expenses	4,497	4,585	4,276	13,378	12,258	16,703
3	Profit before tax and exceptional item (1-2)	1,028	1,257	509	3,027	1,929	2,243
4	Exceptional items [refer note 7,8 and 11]	550	-	-	1,370	1,987	1,987
5	Profit before tax from continuing operations (3 + 4)	1,578	1,257	509	4,397	3,916	4,230
6	Tax expense of continuing operations [refer note 7 and 8]	371	257	66	970	444	447
7	Profit for the period/year from continuing operations (5 - 6)	1,207	1,000	443	3,427	3,472	3,783
	Discontinued operations						
8	Profit/(loss) before tax for the period/year from discontinued operations [refer note 4]	-	169	311	117	862	1,291
9	Tax expense/(credit) of discontinued operations	-	108	27	157	112	147
10	Profit for the period/year from discontinued operations (8 - 9)	-	61	284	(40)	750	1,144
11	Net profit for the period/year (7+10)	1,207	1,061	727	3,387	4,222	4,927
12	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss	(65)	18	(87)	(52)	68	42
	(ii) Income tax relating to items that will not be reclassified to profit or loss	41	(5)	21	38	103	93
	B (i) Items that will be reclassified to profit or loss	(10)	(1)	106	(17)	(39)	(7)
	(ii) Income tax relating to items that will be reclassified to profit or loss	4	-	(39)	6	11	3
	Other comprehensive income, net of taxes	(30)	12	1	(25)	143	131
13	Total comprehensive income for the period/year (11+12)	1,177	1,073	728	3,362	4,365	5,058
14	Paid-up equity share capital (Face value of Rs. 5 each) [refer note 12]	6,000	6,000	3,000	6,000	3,000	3,000
15	Reserves i.e. Other equity						68,154
16	Earnings per share (of Rs. 5 each) [refer note 12]						
	From continuing operations	(not annualised)	(annualised)				
	(a) Basic	1.02	0.85	0.38	2.89	2.94	3.20
	(b) Diluted	1.02	0.84	0.37	2.88	2.92	3.18
	From discontinued operations						
	(a) Basic	-	0.05	0.24	(0.03)	0.63	0.97
	(b) Diluted	-	0.05	0.24	(0.03)	0.63	0.96
	From total operations						
	(a) Basic	1.02	0.90	0.62	2.86	3.57	4.17
	(b) Diluted	1.02	0.89	0.61	2.85	3.55	4.14
	See accompanying notes to the financial results						



BIOCON LIMITED

CIN: L24234KA1978PLC003417 Website: www.biocon.com

Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE - 560 100

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(Rs. in Million, except per equity share data)

Sl. No.	Particulars	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Previous Year
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	ended 31.03.2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	Revenue from operations	17,481	15,722	15,408	47,862	39,856	55,144
	Other income	358	384	256	983	1,210	1,444
	Total income	17,839	16,106	15,664	48,845	41,066	56,588
2	Expenses						
	a) Cost of raw materials and packing materials consumed	5,502	5,143	5,540	15,536	14,320	19,795
	b) Purchases of traded goods	408	556	359	1,361	1,073	1,268
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(137)	(920)	(618)	(2,100)	(1,306)	(2,097)
	d) Employee benefits expense	3,761	3,533	2,944	10,704	8,447	11,653
	e) Finance costs	177	138	186	481	550	709
	f) Depreciation and amortisation expenses	1,440	1,316	1,167	3,998	3,280	4,478
	g) Other expenses	4,376	4,203	3,992	11,886	9,531	13,287
		15,527	13,969	13,570	41,866	35,895	49,093
	Less: Recovery of cost from co-development partners (net)	(871)	(821)	(616)	(2,370)	(2,068)	(2,699)
	Total expenses	14,656	13,148	12,954	39,496	33,827	46,394
3	Profit before share of profit of joint venture and associates, exceptional items and tax (1-2)	3,183	2,958	2,710	9,349	7,239	10,194
4	Share of profit / (loss) of joint venture and associates, net	(32)	(94)	125	(205)	121	9
5	Profit before tax and exceptional items (3+4)	3,151	2,864	2,835	9,144	7,360	10,203
6	Exceptional items (net) [refer note 9 and 10]	-	675	58	675	1,946	1,946
7	Profit before tax (5+6)	3,151	3,539	2,893	9,819	9,306	12,149
8	Tax expense [refer note 4, 7, 8, 9 and 10]	848	1,001	461	2,701	1,714	2,123
9	Profit for the period / year before non-controlling interest (7-8)	2,303	2,538	2,432	7,118	7,592	10,026
10	Non-controlling interest	(275)	(381)	(260)	(870)	(676)	(973)
11	Profit for the period / year (9+10)	2,028	2,157	2,172	6,248	6,916	9,053
12	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss	(146)	(338)	(666)	(873)	(557)	(605)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	45	32	79	112	169	160
	B (i) Items that will be reclassified to profit or loss	155	(265)	1,490	(383)	(1,116)	(432)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(2)	101	(449)	130	379	153
	Total other comprehensive income, net of tax	52	(470)	454	(1,014)	(1,125)	(724)
13	Non-controlling interest	16	112	(413)	171	340	172
14	Other comprehensive income attributable to Shareholders (12+13)	68	(358)	41	(843)	(785)	(552)
	Total comprehensive income attributable to:						
	Shareholders of the Company	2,096	1,799	2,213	5,405	6,131	8,501
	Non-controlling interest	259	269	673	699	336	801
	Total comprehensive income	2,355	2,068	2,886	6,104	6,467	9,302
15	Paid-up equity share capital (Face value of Rs. 5 each)	6,000	6,000	3,000	6,000	3,000	3,000
16	Reserves i.e. Other equity						57,980
17	Earnings per share (of Rs. 5 each) [refer note 12]	(not annualised)	(annualised)				
	(a) Basic	1.71	1.82	1.84	5.28	5.85	7.65
	(b) Diluted	1.71	1.82	1.82	5.27	5.81	7.60
	See accompanying notes to the financial results						



BIOCON LIMITED

CIN: L24234KA1978PLC003417 Website: www.biocon.com

Registered office : 20TH KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE - 560 100

SEGMENT DETAILS OF UNAUDITED CONSOLIDATED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(Rs. in Million)

Particulars	3 months ended 31.12.2019	3 months ended 30.09.2019	3 months ended 31.12.2018	9 months ended 31.12.2019	9 months ended 31.12.2018	Previous Year ended 31.03.2019
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Segment revenue						
a. Small molecules	5,438	5,296	4,689	15,530	13,009	17,728
b. Biologics	5,882	5,161	4,486	15,939	10,658	15,169
c. Branded formulations	1,573	1,283	2,122	4,190	5,234	6,564
d. Research services	5,191	4,646	4,671	14,046	12,917	18,256
Total	18,084	16,386	15,968	49,705	41,818	57,717
Less: Inter-segment revenue	(603)	(664)	(560)	(1,843)	(1,962)	(2,573)
Net sales / Income from continuing operations	17,481	15,722	15,408	47,862	39,856	55,144
Segment results						
Profit before interest and tax from each segment						
a. Small molecules	1,042	1,156	976	3,235	2,573	3,254
b. Biologics #	1,450	1,268	1,331	4,578	2,508	3,977
c. Branded formulations #	176	27	274	176	573	621
d. Research services	1,067	988	1,068	2,926	2,868	4,154
Total	3,735	3,439	3,649	10,915	8,522	12,006
Less: Interest	80	56	104	231	306	388
Other un-allocable expenditure / (income), net	504	519	710	1,540	856	1,415
Profit before tax and before exceptional items #	3,151	2,864	2,835	9,144	7,360	10,203
Segment assets						
a. Small molecules	23,972	22,269	19,573	23,972	19,573	20,068
b. Biologics	58,302	55,288	45,845	58,302	45,845	47,601
c. Branded formulations	2,242	2,043	3,656	2,242	3,656	3,178
d. Research services	40,280	39,556	33,998	40,280	33,998	37,035
	1,24,796	1,19,156	1,03,072	1,24,796	1,03,072	1,07,882
e. Unallocable	11,108	12,128	13,159	11,108	13,159	14,042
Total segment assets	1,35,904	1,31,284	1,16,231	1,35,904	1,16,231	1,21,924
Segment liabilities						
a. Small molecules	6,325	5,891	4,685	6,325	4,685	4,965
b. Biologics	14,436	15,862	10,282	14,436	10,282	12,152
c. Branded formulations	1,096	861	2,692	1,096	2,692	2,416
d. Research services	18,475	18,654	15,893	18,475	15,893	17,351
	40,332	41,268	33,552	40,332	33,552	36,884
e. Unallocable	22,731	19,760	17,876	22,731	17,876	17,971
Total segment liabilities	63,063	61,028	51,428	63,063	51,428	54,855
Capital employed						
a. Small molecules	17,647	16,378	14,888	17,647	14,888	15,103
b. Biologics	43,866	39,426	35,563	43,866	35,563	35,449
c. Branded formulations	1,146	1,182	964	1,146	964	762
d. Research services	21,805	20,902	18,105	21,805	18,105	19,684
	84,464	77,888	69,520	84,464	69,520	70,998
e. Unallocable	(11,623)	(7,632)	(4,717)	(11,623)	(4,717)	(3,929)
Total capital employed	72,841	70,256	64,803	72,841	64,803	67,069
# includes share of profit/loss of joint venture and associates						



Biocon Limited

Unaudited financial results for the quarter and nine months ended December 31, 2019

Notes:

1. The unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2019 in respect of Biocon Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 23, 2020. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
2. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The consolidated financial results include the financial results of the parent company Biocon Limited and the financial results of the following subsidiaries:

- Syngene International Limited ('Syngene')
- Biocon Research Limited ("BRL")
- Biocon Pharma Limited
- Biocon Academy
- Biocon SA
- Biocon SDN. BHD
- Biocon FZ LLC
- Biocon Biologics Limited
- Biocon Pharma Inc.
- Biocon Biologics India Limited ("BBIL")
- Biocon Healthcare SDN. BHD
- Bicara Therapeutics Inc. ("Bicara")
- Biocon Pharma Ireland Limited
- Biocon Pharma UK Limited
- Biocon Biosphere Limited
- Biocon Biologics Inc.
- Syngene USA Inc.

Biocon Limited and its subsidiaries are collectively referred to as 'the Group'. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust and Syngene International Limited Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC and share of investment in the associates i.e. Iatrica Inc., if any under the equity method.

4. Discontinued/ Discontinuing operations:

Consequent to the approvals received from the Board of Directors on October 26, 2017 and from the shareholders on December 07, 2017, the Company has transferred the business undertaking related to manufacturing and commercialisation of Biosimilars, Insulins and drug substance manufactured in the GPP facility under the Biologics segment of the Group on a going concern basis by way of slump sale to BBIL effective May 01, 2019 for a consideration of Rs 7,054 million.



Biocon Limited

Unaudited financial results for the quarter and nine months ended December 31, 2019

Also, consequent to the approval received from the Company's Board of Directors on June 17, 2019, the Company transferred Branded Formulations (BFI) business on a going concern basis by way of a slump sale to BBIL effective August 01, 2019 for a consideration of Rs 621 million. Gain on disposal of assets / liabilities amounting to Rs 121 million which is exceptional in nature has been disclosed under the discontinued operations.

Consequential tax impact of Rs 29 million and Rs 44 million has been recorded for the quarter and nine months ended December 31, 2019 respectively in the standalone and consolidated financial results which is included within tax expense.

Accordingly, results of Biologics and BFI business for the nine months ended December 31, 2019 and comparatives for previous periods has been disclosed as discontinued operations in the standalone results.

The above slump sale of Biologics and BFI businesses to BBIL did not have any material impact on the consolidated results.

5. Segment Reporting in Consolidated financial results: Based on the "management approach" as defined in Ind AS 108-Operating Segments, the Chief Operating Decision Maker evaluates the Group's performance and allocates resources based on an analysis of various performance indicators by business segments. Accordingly, information has been presented along these business segments. The accounting principles used in the preparation of these financial results are consistently applied to record revenue and expenditure in individual segments.
6. Effective April 1, 2019, the Group has adopted Ind AS 116 "Leases" on all lease contracts existing on April 1, 2019 using the modified retrospective method and has taken the cumulative adjustment to retained earnings, on the date of initial application. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. On transition, the adoption of the standard resulted in recognition of Right-of-use assets (ROU) of Rs 353 million and a lease liability of Rs 334 million. The cumulative effect of applying the standard resulted in Rs 24 million being debited to retained earnings, net of taxes. The effect of this adoption did not have a material impact on the results for the quarter and nine months ended December 31, 2019.
7. During the quarter ended June 30, 2019, pursuant to group entities restructuring the Company sold its investment in the equity shares of Biocon Biologics Limited, United Kingdom (BUK), a wholly owned subsidiary to BBIL for a consideration of Rs 10,810 million and received dividend of Rs 456 million from BUK. Gain arising from such sale of equity shares, including dividend income, amounting to Rs 820 million is recorded as an exceptional item in the standalone financial results. Consequential tax of Rs 166 million is included within tax expense from continuing operations in standalone and consolidated financial results.
8. During the quarter ended December 31, 2019, the Company has entered into a License Agreement with Bicara, a wholly owned subsidiary, pursuant to which the Company has granted a license to develop, manufacture and commercialize fusion proteins. Gain on such licensing of Rs 550 million has been recorded as an exceptional income in the standalone financial results of the Company. Consequential tax impact of Rs 192 million has been recorded in the standalone and consolidated financial results which is included within tax expense.



Biocon Limited

Unaudited financial results for the quarter and nine months ended December 31, 2019

9. Pursuant to a fire incident on December 12, 2016 at Syngene, certain fixed assets, inventory and other contents in one of the buildings were damaged. Syngene lodged an estimate of loss with the insurance company and the survey is currently ongoing. Syngene had recorded a loss of Rs 1,057 million arising from such incident and also recognized a minimum insurance claim receivable for equivalent amounts in respective periods till December 31, 2019. Syngene has also received the disbursements of Rs 1,770 million from the insurance company against the loss till December 31, 2019. The aforementioned receivable and the disbursements from the insurance claim has been presented on a net basis as Rs 713 under Exceptional items in these financial results. Consequential tax and non-controlling interest of Rs 254 million and Rs 137 million respectively is included within tax expense and non-controlling interest in consolidated financial results.

In addition, Syngene is in the process of determining its final claim for loss of fixed assets and Business Interruption and has accordingly not recorded any further claim arising therefrom at this stage.

10. During the nine months ended December 31, 2018, Equillum initiated its initial public offering (IPO) process and consequently had changes in its Board composition, which resulted in loss of significant influence over the investee. In accordance with Ind AS 28: Investments in Associates and Joint Ventures, the Company fair valued its investment on the date of loss of significant influence and the anti-dilutive rights on the date of IPO which resulted in a gain of Rs 1,762 million, net of tax expenses of Rs 184 million for the year ended March 31, 2019, which has been disclosed as an Exceptional item for the nine months ended December 31, 2018 and year ended March 31, 2019.
11. During the nine months ended December 31, 2018 and year ended March 31, 2019, the Company along with its subsidiary BRL sold 1,000,000 and 6,597,130 equity shares of Rs 10 each of Syngene respectively in the open market. Gain arising from such sale of equity shares amounting to Rs 347 and Rs 1,987 has been recorded as exceptional item in the standalone financial results for the nine months ended December 31, 2018 and year ended March 31, 2019 respectively.

The gain arising from such sale of equity shares for the nine months ended December 31, 2018 and year ended March 31, 2019 has been accounted in equity reserves in the consolidated financial results, as there was no loss of control.

12. The Company has allotted 600,000,000 equity shares of Rs 5/- each fully paid up as bonus shares on June 21, 2019 in the ratio of 1:1 (One equity shares of Rs 5/- each for every one equity share of Rs 5/- each held in the Company as on the record date i.e., June 13, 2019) by capitalisation of securities premium account and general reserve. In accordance with Ind AS 33, Earnings per share, the earnings per share data has been adjusted to give effect to the bonus issue for all periods presented.
13. Prior period/ year figures have been reclassified wherever required to conform to the classification of the current period/ year. Also refer note 4 above.

For and on behalf of the Board of Directors of Biocon Limited



Kiran Mazumdar-Shaw
Chairperson and Managing Director

Bangalore,
January 23, 2020

